Contrarian
The Biosimilar Discount Paradox
The promise of biosimilars was straightforward enough to fit on a campaign banner: near-identical versions of expensive biologic drugs, at...
Read more
Ain’t What’s Paid — And Never Was
A pricing benchmark that the industry itself nicknamed "Ain't What's Paid" would seem unlikely to survive the reputational damage. Average...
Read more
The Gold Standard That Comes with Caveats
If you have read an academic paper, policy brief, or investor report that estimates a drug's net price in the...
Read more
The Ingredient Illusion
Search interest in ultra‑processed food risks, seed oil controversies, additive toxicity debates, and metabolic health policy interventions has surged across...
Read more
The Expanding Frontier of Abnormal
Search interest in advanced blood panels, inflammatory biomarker mapping, metabolic precision diagnostics, and early-detection screening packages has accelerated across physician...
Read more
The Subscription Clinic Economy
The waiting room has begun to resemble a product funnel. The growth of subscription-based peptide clinics signals a deeper transformation...
Read more
The Politics of Therapeutic Legitimacy
Medicine prefers to imagine itself as insulated from politics. Reality is less accommodating. The recent association of peptide deregulation discourse...
Read moreThe Bypass Economy in Medicine
Direct‑to‑consumer healthcare services have quietly constructed a parallel infrastructure for medical access. Telehealth platforms prescribe medications after brief video consultations....
Read more
Self-Tracking Has Become a Form of Health Literacy, and a Source of Noise
A new kind of literacy is spreading through the public: people can read their own physiologic dashboards. They discuss REM...
Read more
When Healing Harms: The Unseen Costs of Healthcare Sustainability
A gleaming solar array atop a hospital wing promises reduced electricity bills and a smaller carbon footprint—but what happens when...
Read more
Performative Oncology: The Rise of Cancer Influencers and the Erosion of Evidence
The Spectacle of Sickness There is a calculated rhythm to the videos. A grainy close-up of someone solemnly describing their...
Read more
Debunking Certainty: How the MAHA Report by Robert F. Kennedy Jr. Thrives on Logical Fallacies
When Robert F. Kennedy Jr. released the eagerly anticipated yet deeply contentious MAHA report earlier this year, it instantly polarized...
Read more
FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more